A new report on cancer treatment highlights progress in treating small cell lung cancer, an aggressive form of the disease that can be difficult to control. Researchers have reported encouraging results from combining immunotherapy medicines, offering further evidence that treatment strategies targeting the immune system may improve outcomes for some patients.
What the Clinical Trial Found
The Phase 3 DeLLphi-305 trial evaluated Imdelltra (tarlatamab) alongside Imfinzi (durvalumab) as maintenance treatment for patients with extensive-stage small cell lung cancer whose disease had not progressed after initial treatment with chemotherapy and Imfinzi.
The combination reduced the risk of death by 58% compared with Imfinzi alone. Median overall survival reached 21.1 months, compared with 12.7 months in the comparison group—an improvement of 8.4 months. Nearly 80% of patients receiving the combination were alive at one year, compared with 53% of those receiving Imfinzi alone.
How the Combination Works
Imdelltra helps immune-system T cells recognise and attack cancer cells carrying a protein called DLL3. Imfinzi works by blocking PD-L1, a protein that can help cancer cells evade immune responses. The medicines therefore target different parts of the process involved in the body’s response to cancer.
The study also reported a reduction in the risk of disease progression or death. However, treatment-related side effects were more common with the combination than with Imfinzi alone, making medical supervision essential.
What Happens Next?
The findings offer encouraging evidence for a potential treatment option in an aggressive form of lung cancer. Further regulatory review will be important in determining whether the combination can be used more widely in this treatment setting.
The results are specific to the patients and treatment approach studied; they do not establish that the combination is suitable for every person with lung cancer.
